Arcus Biosciences, Inc. (RCUS) is a Biotechnology company in the Healthcare sector, currently trading at $23.01. It has a SharesGrow Score of 55/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Analyst consensus target is RCUS = $28 (+21.7% upside).
Valuation: RCUS trades at a trailing Price-to-Earnings (P/E) of -6.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.55.
Financials: revenue is $247M, +40.2%/yr average growth. Net income is $353M (loss), growing at -10.6%/yr. Net profit margin is -142.9% (negative). Gross margin is 96% (+8.5 pp trend).
Balance sheet: total debt is $99M against $631M equity (Debt-to-Equity (D/E) ratio 0.16, conservative). Current ratio is 4.36 (strong liquidity). Debt-to-assets is 8.7%. Total assets: $1.1B.
Analyst outlook: 15 / 18 analysts rate RCUS as buy (83%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 90/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 70/100 (Pass), Future 88/100 (Pass), Income 10/100 (Fail).
